Have a say in the future of psychiatric medicine
Drug development is challenging, and open-source can curb it.
Elata is a DAO and incubator of high-impact psychiatric drug development efforts.
Anyone can join Elata and own a piece of what we believe will be the decentralized future of mental health pharmaceutical development.
Elata is a DAO and incubator of high-impact psychiatric drug development efforts.
Anyone can join Elata and own a piece of what we believe will be the decentralized future of mental health pharmaceutical development.
Clone
Our mission is to solve problems in psychiatry using open-source principles.
15% +
Of people - or close to 800 million - struggle with a mental health disorder globally.
13% +
Of adults in the United States take a first, second, or third-generation antidepressant.
$25bn +
Of private transaction volume in neuropsychiatry through the past year, marking an increasing interest in the field.
80% +
Of technology spinouts originating in academia and government fail, prompting the need for a superior spinout model.
GPT-powered specialty news aggregator
We're in the early phases of developing Elata News - a fully open-source GPT-powered content aggregator for everything DeSci, Neuropsychiatry, and more.
Built for community
Native sharing on all devices and geared towards seamless community engagement.
Decentralized governance
All executive matters relating to Elata News will be added to the Elata governance process, where tokenholders make the final call.
Narrow expertise
Includes select, yet highly relevant topics from trustworthy sources, according to Elata's community.
100% open-source
Elata News is a metonym to our mission - it's 100% open-source and transparent, meaning anyone can see what's happening and contribute.
Elata's model aims to serve all contributors
For holders
It is no secret that drug development is a pricey endeavor, and it is no surprise that private markets are generally uninterested in investing in projects with low upside potential.
Elata aims to solve these issues by pushing high upside potential projects, unlocking royalty streams and cashflows stemming from licensing agreements to support DAO continuity.
Note: Due to regulatory uncertainty, rules may apply to certain jurisdictions and perception of securities issuance, and Elata currently has no standard in place for such events. As such, related matters will be collectively addressed on a per-project basis where safeguard implementation and compliance may occur.
For developers
Elata is forming a psychiatric innovation unit to advance novel compound research, inviting pioneering researchers to steer early-stage drug development.
Elata seeks to unify the psychiatric research community, enhancing collaboration and aligning incentives through a distributed and community-focused approach.
For patients
In neuropsychiatry's long-term, there is no misalignment between patient, investor, and developer interest. Which is why developing an open community that patients can use is the key and most important part of Elata.
We prioritize patient outcomes by fostering an open community, and generating signal via. experimental medicine outcomes, ensuring product-centricity, scientific advancements, symptom and syndrome-based treatment approaches, and funding interests align closely with the needs of patients.
Frequently asked questions
Reach out to us if you have questions that aren't answered here.
How does Elata work?
Elata is an open innovation effort broadly focused on early-stage drug development in neuropsychiatry, operating within an area known as decentralized science (DeSci). The DeSci movement aims to use blockchain networks to create an open ecosystem around scientific research, ranging from many distinct therapeutic areas - and more specifically - to align incentives for all stakeholders, something that has traditionally been very difficult in open-source communities. Our goal is to create more effective spinouts than those at traditional institutions by implementing a modular organizational structure in which the hub is an open, transparent, and decentralized information exchange.
To learn more, reference our Documentation or Due Diligence FAQ section.
To learn more, reference our Documentation or Due Diligence FAQ section.
What is the advantage of Elata?
Elata is pooling expertise and financial capital to create an all-encompassing constituency and organizational innovation unit supporting early-stage drug development in psychiatry. Our solution aims to operate at the crossroads of various disciplines, and we orient ourselves to push a diversified portfolio of medicines forward to maximize impact for investors, external partners, contributors, and ultimately patients.
How can I get involved?
At some point in the near future, you will be able to obtain an Elata token which will allow you to stake and therefore cast a vote pertaining to initiatives we engage in. Besides that, communications will be streamed primarily through our Discord Server, where members can engage in information sharing, vote tracking, project screening, and news updates. Besides Discord, we regularly update our social media accounts as a way of communicating with those who wish to partially engage with our community. We primarily use X/Twitter and LinkedIn for these purposes.
What differentiates Elata's strategy?
Since the inception of pharmacotherapy for mental health - across every major category including psychotic, anxious, and depressive disorders - drug developers have been largely focused on monoamine drug targets (serotonin, dopamine, and norepinephrine receptors) to guide their development strategy. Nearly every major neuropsychiatric medicine on the market today, whether it be SSRIs or atypical antipsychotics, works through monoamine targets. However, we view this strategy as flawed and outdated - what it fails to account for is that patient groups in psychiatry tend to be extremely heterogeneous, and the spectrum of who will respond to what is wide.
Our strategy is different because we put patients first by segmenting phenotypic and neurological traits to reduce the amount of heterogeneity and create subpopulations, allowing for more targeted treatment plans and approval likelihood amongst regulatory bodies. In the ~ 75 years of data we have on psychiatric drugs, one thing is very clear: the need for novel and diverse targets as well as symptomatically and syndromally driven treatments is greater than ever before. DSM criteria is overly broad, and our goal is to pursue opportunities that do not excessively rely on DSM.
Our strategy is different because we put patients first by segmenting phenotypic and neurological traits to reduce the amount of heterogeneity and create subpopulations, allowing for more targeted treatment plans and approval likelihood amongst regulatory bodies. In the ~ 75 years of data we have on psychiatric drugs, one thing is very clear: the need for novel and diverse targets as well as symptomatically and syndromally driven treatments is greater than ever before. DSM criteria is overly broad, and our goal is to pursue opportunities that do not excessively rely on DSM.
Why a DAO instead of an NGO or C-Corp?
A DAO is the most sensible solution to our issue, as it effectively combines aspects of centralization and decentralization, is modular, and generally adopts characteristics from corporations and non-profits while remaining fundamentally distinct from both.
With regards to neuropsychiatry, the field has long struggled with data silos, poor alignment of incentives, riskiness, and innovation. Corporations have divested from neuropsychiatry and struggle with incentive alignments whereas non-profits and public spinouts struggle heavily with efficiency, human capital, and productization.
We believe Elata is a practical way to solve issues in neuropsychiatry for the following reasons:
• A DAO is decentralized, open-source, and perhaps even more focused on ethics, meaning anyone (especially patients) can contribute to and partake in upside of successful drug development efforts on-chain.
• Is able to cover the intense costs typically associated with drug development using funds from the DAO treasury.
• Is scalable, modular (many initiatives can be executed simultaneously), and in turn, more efficient.
With regards to neuropsychiatry, the field has long struggled with data silos, poor alignment of incentives, riskiness, and innovation. Corporations have divested from neuropsychiatry and struggle with incentive alignments whereas non-profits and public spinouts struggle heavily with efficiency, human capital, and productization.
We believe Elata is a practical way to solve issues in neuropsychiatry for the following reasons:
• A DAO is decentralized, open-source, and perhaps even more focused on ethics, meaning anyone (especially patients) can contribute to and partake in upside of successful drug development efforts on-chain.
• Is able to cover the intense costs typically associated with drug development using funds from the DAO treasury.
• Is scalable, modular (many initiatives can be executed simultaneously), and in turn, more efficient.